檢索結果 - Lecia V. Sequist

Refine Results
  1. 1
    <i>AJRCCM</i>: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.The Shifting Landscape for Lung Cancer: Past, Present, and Future

    <i>AJRCCM</i>: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.The Shifting Landscape for Lung Cancer: Past, Present, and Future 由 Anil Vachani, Lecia V. Sequist, Avrum Spira

    出版 2017
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Genetic Changes in Squamous Cell Lung Cancer: A Review

    Genetic Changes in Squamous Cell Lung Cancer: A Review 由 Rebecca S. Heist, Lecia V. Sequist, Jeffrey A. Engelman

    出版 2012
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Targeting<i>EGFR</i>Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates

    Targeting<i>EGFR</i>Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates 由 Catherine B. Meador, Lecia V. Sequist, Zofia Piotrowska

    出版 2021
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Update to Rociletinib Data with the RECIST Confirmed Response Rate

    Update to Rociletinib Data with the RECIST Confirmed Response Rate 由 Lecia V. Sequist, Jean‐Charles Soria, D. Ross Camidge

    出版 2016
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  5. 5
    Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

    Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management 由 Alissa J. Cooper, Lecia V. Sequist, W. Marston Linehan

    出版 2022
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma

    Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma 由 Zofia Piotrowska, Florian J. Fintelmann, Lecia V. Sequist, Balkrishna Jahagirdar

    出版 2018
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  7. 7
    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin 由 Matthew G. Oser, Matthew J. Niederst, Lecia V. Sequist, Jeffrey A. Engelman

    出版 2015
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  8. 8
    The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

    The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients 由 Lecia V. Sequist, Sunitha Nagrath, Mehmet Toner, Daniel A. Haber, Thomas J. Lynch

    出版 2009
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?

    Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? 由 Subba R. Digumarthy, Atul Padole, Roberto Lo Gullo, Lecia V. Sequist, Mannudeep K. Kalra

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

    Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer 由 Meghan Campo, H. Al-Halabi, Melin J. Khandekar, Alice T. Shaw, Lecia V. Sequist, Henning Willers

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  11. 11
    Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

    Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Thera... 由 H. Al-Halabi, Karl Sayegh, Subba R. Digamurthy, Andrzej Niemierko, Zofia Piotrowska, Henning Willers, Lecia V. Sequist

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

    Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib 由 Lecia V. Sequist, Zofia Piotrowska, Matthew J. Niederst, Rebecca S. Heist, Subba R. Digumarthy, Alice T. Shaw, Jeffrey A. Engelman

    出版 2015
    獲取全文 獲取全文
    Carta
    加到收藏夾
    Saved in:
  13. 13
    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors 由 Sarah B. Goldberg, Geoffrey R. Oxnard, Subba R. Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?

    Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT? 由 Subba R. Digumarthy, Atul Padole, Shivam Rastogi, Melissa C. Price, Meghan J. Mooradian, Lecia V. Sequist, Mannudeep K. Kalra

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

    FGFR1 Amplification in Squamous Cell Carcinoma of The Lung 由 Rebecca S. Heist, Mari Mino‐Kenudson, Lecia V. Sequist, Swathi Tammireddy, L Morrissey, David C. Christiani, Jeffrey A. Engelman, A. John Iafrate

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

    Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer 由 Raymond H. Mak, Subba R. Digumarthy, Alona Muzikansky, Jeffrey A. Engelman, Jo-Anne O. Shepard, Noah C. Choi, Lecia V. Sequist

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer 由 Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

    The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies 由 Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

    EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer 由 April F. Eichler, Kristopher T. Kahle, D. L. Wang, Victoria A. Joshi, Henning Willers, J. A. Engelman, Thomas J. Lynch, Lecia V. Sequist

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC

    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC 由 Raymond H. Mak, Elizabeth Doran, Alona Muzikansky, Josephine Kang, Joel W. Neal, Noah C. Choi, Henning Willers, David M. Jackman, Lecia V. Sequist

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: